[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Samuels SE, Knowles AL, Tilignac T, Debiton E, Madelmont JC, Attaix D: Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice. Cancer Res; 2000 Sep 1;60(17):4968-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice.
  • The impact of cancer cachexia and chemotherapy on small intestinal protein metabolism and its subsequent recovery was investigated.
  • Cancer cachexia was induced in mice with colon 26 adenocarcinoma, which is a small and slow-growing tumor characteristic of the human condition, and can be cured with 100% efficacy using an experimental nitrosourea, cystemustine (C6H12ClN3O4S).
  • Both healthy mice and tumor-bearing mice were given a single i.p. injection of cystemustine (20 mg/kg) 3 days after the onset of cachexia.
  • Cancer cachexia led to a reduced in vivo rate of protein synthesis in the small intestine relative to healthy mice (-13 to -34%; P < 0.05), resulting in a 25% loss of protein mass (P < 0.05), and decreased villus width and crypt depth (P < 0.05).
  • In treated mice, acute cytotoxicity of chemotherapy did not promote further wasting of small intestinal protein mass, nor did it result in further damage to intestinal morphology.
  • In contrast, mucosal damage and a 17% reduction in small intestinal protein mass (P < 0.05) were evident in healthy mice treated with cystemustine, suggesting that the effects of chemotherapy on the small intestine in a state of cancer cachexia are not additive, which was an unexpected finding.
  • Complete and rapid recovery of small intestinal protein mass in cured mice resulted from an increase in the rate of protein synthesis compared with healthy mice (23-34%; P < 0.05).
  • Northern hybridizations of mRNA encoding components of the major proteolytic systems suggested that proteolysis may not have mediated intestinal wasting or recovery.
  • A major clinical goal should be to design methods to improve small intestinal protein metabolism before the initiation of chemotherapy.
  • [MeSH-major] Adenocarcinoma / complications. Antineoplastic Agents / toxicity. Cachexia / metabolism. Colonic Neoplasms / complications. Intestine, Small / metabolism. Nitrosourea Compounds / toxicity. Proteins / metabolism
  • [MeSH-minor] Animals. Atrophy. Blotting, Northern. Cathepsin B / biosynthesis. Cathepsin B / genetics. Cathepsin B / metabolism. Eating. Gene Expression. Male. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Protein Biosynthesis. Ubiquitins / biosynthesis. Ubiquitins / genetics. Ubiquitins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10987314.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Proteins; 0 / Ubiquitins; 79955-36-5 / N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


2. Dickson MA, Shah MA, Rathkopf D, Tse A, Carvajal RD, Wu N, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK: A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol; 2010 Nov;66(6):1113-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical activity included 2 partial responses in small bowel cancer and bladder cancer and 1 complete response in mucosal melanoma.
  • Clinical benefit was correlated with the presence of wild-type p53.
  • Of 25 patients with colorectal cancer, 11 had as best response SD for >3 m (median 6 m, range 4.2-15.4 m), despite failing ≥1 irinotecan-containing regimen.
  • CONCLUSIONS: Treatment with flavopiridol and FOLFIRI is a safe and effective regimen.
  • Clinical activity is encouraging and includes prolonged stable disease in patients with irinotecan-refractory colorectal cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2527-36 [11489836.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4209-19 [11751522.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):549-55 [12813134.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] Invest New Drugs. 2004 Aug;22(3):315-22 [15122079.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jun 15;201(2):589-95 [8002990.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2973-8 [8674031.001]
  • [Cites] Curr Opin Genet Dev. 1996 Feb;6(1):56-64 [8791491.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1876-83 [10430095.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):889-98 [15681535.001]
  • [Cites] Contemp Clin Trials. 2005 Apr;26(2):131-40 [15837436.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3836-45 [15897584.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):249-53 [15978659.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5935-41 [16115936.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Haematologica. 2006 Mar;91(3):390-3 [16503551.001]
  • [Cites] Invest New Drugs. 2006 Jul;24(4):305-10 [16683073.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1158-65 [16600980.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5841-6 [17908977.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2312-20 [18381438.001]
  • [Cites] Clin Lung Cancer. 2008 May;9(3):160-5 [18621626.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2168-81 [11489790.001]
  • (PMID = 20953860.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA067819; United States / NCI NIH HHS / CA / R01CA67819
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 0 / Protein Kinase Inhibitors; 45AD6X575G / alvocidib; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS195344; NLM/ PMC2957673
  •  go-up   go-down


3. Hahn SM, Putt ME, Metz J, Shin DB, Rickter E, Menon C, Smith D, Glatstein E, Fraker DL, Busch TM: Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res; 2006 Sep 15;12(18):5464-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy.
  • PURPOSE: A phase II trial of Photofrin-mediated i.p. photodynamic therapy shown in a previous report limited efficacy and significant acute, but not chronic, toxicity.
  • A secondary aim of this trial and the subject of this report is to determine Photofrin uptake in tumor and normal tissues.
  • Photofrin uptake was measured by spectroflurometric analysis of drug extracted from tumor and normal tissues removed at surgery.
  • Differences in drug uptake among these tissues were statistically considered using mixed-effects models.
  • In normal tissues, drug uptake significantly (P<0.0001) differed as a function of seven different tissue types.
  • In the toxicity-limiting tissue of intestine, the model-based mean (SE) Photofrin level was 2.70 ng/mg (0.32 ng/mg) and 3.42 ng/mg (0.24 ng/mg) in full-thickness large and small intestine, respectively.
  • In tumors, drug uptake significantly (P=0.0015) differed as a function of patient cohort: model-based mean Photofrin level was 3.32 to 5.31 ng/mg among patients with ovarian, gastric, or small bowel cancer; 2.09 to 2.45 ng/mg among patients with sarcoma and appendiceal or colon cancer; and 0.93 ng/mg in patients with pseudomyxoma.
  • Ovarian, gastric, and small bowel cancers showed significantly higher Photofrin uptake than full-thickness large and/or small intestine.
  • However, the ratio of mean drug level in tumor versus intestine was modest (<or=2.31).
  • CONCLUSIONS: Some selectivity is found in Photofrin uptake between tumor and normal tissues of the peritoneal cavity, but absolute differences in drug uptake relative to toxicity-limiting normal tissues (intestine) are small.
  • This narrow differential in drug selectivity likely contributes to a narrow window in therapeutic application, which has been previously reported.
  • [MeSH-minor] Biopsy. Cohort Studies. Female. Gastrointestinal Neoplasms / drug therapy. Humans. Injections, Intraperitoneal. Models, Biological. Organ Specificity. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000681.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA-87971; United States / NCI NIH HHS / CA / R01 CA-85831
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


Advertisement
4. Liu ZF, Jiao SC, Yang JL, Dai GH: [Clinical research of 120 cases of primary small intestine malignant tumor]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar;30(3):602-4, 607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical research of 120 cases of primary small intestine malignant tumor].
  • OBJECTIVE: To study the clinical and pathological features, diagnosis, therapy and prognosis of primary small intestine malignant tumor.
  • METHODS: A retrospective analysis was performed on the clinical data from the 120 cases of primary small intestine malignant tumor.
  • Most tumors originated in the duodenum (54.1%), and adenocarcinoma (55.8%) was the main pathological type.
  • The median survival time of the patients was 19.2 months and the 1-year survival rate was 55.4%.
  • Chemotherapy did not seem to significantly improve the 1-year survival rate of the patients (P=0.842).
  • CONCLUSION: Primary small intestine malignant tumors lack specific clinical manifestations and surgical resection should be performed as early as possible.
  • [MeSH-major] Adenocarcinoma. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / surgery. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20335150.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Kanemoto K, Kurishima K, Ishikawa H, Shiotani S, Satoh H, Ohtsuka M: Small intestinal metastasis from small cell lung cancer. Intern Med; 2006;45(16):967-70
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small intestinal metastasis from small cell lung cancer.
  • A 71-year-old man who had small cell lung cancer was referred to our institution.
  • Before starting chemotherapy, anemia progressed and stool examination was positive for occult blood.
  • An abdominal computed tomography scan with contrast medium enhancement of the gastrointestinal tract disclosed a small intestinal tumor.
  • Histological examination after the surgery confirmed that the tumor was metastasis of lung cancer.
  • Although clinically apparent metastases of lung cancer to the small intestine are rare and are reported to have a poor prognosis, early detection and intervention might enhance the chance of survival.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Intestinal Neoplasms / secondary. Intestine, Small. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Survival. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16974060.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF: Surgically treated primary malignant tumor of small bowel: a clinical analysis. World J Gastroenterol; 2010 Mar 28;16(12):1527-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically treated primary malignant tumor of small bowel: a clinical analysis.
  • AIM: To evaluate the clinical presentation, treatment and survival of patients with primary malignant tumor of small bowel (PMTSB).
  • RESULTS: The most common initial clinical features of the patients were intermittent abdominal discomfort or vague abdominal pain (67.4%), abdominal mass (31.2%), bowel obstruction (24.1%), hemotochezia (21.3%), jaundice (16.3%), fever (14.2%), coexistence of bowel perforation and peritonitis (5.7%), coexistence of gastrointestinal bleeding and shock (5.0%), and intraabdominal bleeding (1.4%).
  • Ileum was the most common site of tumor (44.7%), followed by jejunum (30.5%) and duodenum (24.8%).
  • Segmental bowel resection (n = 81) was the most common surgical procedure, followed by right hemi-colectomy (n = 15), pancreaticoduodenectomy (n = 10), and others (n = 19).
  • Twenty-seven adenocarcinoma patients and 13 malignant lymphoma patients received adjuvant chemotherapy with 5-fluorouracil and cyclophosphamide, adriamycin, vincristine and prednisone, respectively.
  • The median survival time of PMTSB patients was 20.3 mo.
  • Gastrointestinal stromal tumor was observed in 80.0% (20/25), 72.0% (18/25) and 36.0% (9/25) of the patients, respectively.
  • Malignant lymphoma was demonstrated in 69.2% (9/13), 30.8% (4/13) and 0% (0/13) of the patients, respectively.
  • CONCLUSION: En bloc resection is the principal therapy for most PMTSB and chemotherapy is the important treatment modality for malignant lymphoma and other malignant tumors of small bowel which cannot be radically removed.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoid Tumor / surgery. Digestive System Surgical Procedures. Gastrointestinal Stromal Tumors / surgery. Intestinal Neoplasms / surgery. Intestine, Small / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):731-41 [15966194.001]
  • [Cites] Cancer Imaging. 2006;6:209-12 [17208678.001]
  • [Cites] World J Gastroenterol. 2007 Jan 21;13(3):432-7 [17230614.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):39-45 [17240306.001]
  • [Cites] Chirurgia (Bucur). 2006 Sep-Oct;101(5):477-81 [17278638.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Mar;19(2):143-9 [17355111.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):229-35 [17372046.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):129-34 [17419246.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2263-9 [17549572.001]
  • [Cites] Arch Surg. 2009 Jul;144(7):670-8 [19620548.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Am J Surg. 2000 Jan;179(1):37-41 [10737576.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):727-32 [11462914.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83 [12153595.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):469-81 [14713260.001]
  • [Cites] Int Surg. 2004 Jan-Mar;89(1):21-6 [15085993.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] AJR Am J Roentgenol. 1989 May;152(5):995-8 [2705358.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1994 Feb;15(1):46-50 [8082141.001]
  • [Cites] Ann Surg Oncol. 1995 Jan;2(1):26-31 [7834450.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1153-8 [9373284.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1440-4 [10424748.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • (PMID = 20333796.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2846261
  •  go-up   go-down


7. Shehata M, Chu F, Saunders V, Kam PC, Links M, Morris DL: Peritoneal carcinomatosis from colorectal cancer and small bowel cancer treated with peritonectomy. ANZ J Surg; 2006 Jun;76(6):467-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis from colorectal cancer and small bowel cancer treated with peritonectomy.
  • BACKGROUND: This study aims to assess the survival of patients who underwent peritonectomy, to assess the morbidity and mortality associated with the procedure and to review the published reports on the survival of patients with peritoneal spread of colorectal cancer (CRC).
  • METHODS: Peritonectomy involves resection of all visible peritoneal tumour and is followed by heated intraperitoneal chemotherapy.
  • Peritonectomy with heated intraperitoneal chemotherapy is associated with a 3-year survival of 30-50% in patients with low peritoneal cancer index (PCI) with peritoneal carcinomatosis from CRC.
  • This study describes 22 patients with peritoneal spread of gastrointestinal cancer treated with peritonectomy between 1996 and March 2005.
  • Twenty of these patients had primary colorectal cancer and two patients had primary small bowel cancer.
  • We found that those patients with all macroscopic residual tumour removed at the end of the procedure (completeness of cancer resection, CCR O) had improved 24-month survival compared with patients in whom there was incomplete tumour resection (53.3% survival vs 22.2%, respectively, P = 0.024).
  • [MeSH-major] Carcinoma / mortality. Carcinoma / surgery. Intestinal Neoplasms / pathology. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / surgery. Postoperative Complications
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768770.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


8. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS: Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg; 2009 Jan;249(1):63-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.
  • BACKGROUND: Previous studies have shown an increasing incidence of small bowel tumors in the United States.
  • Our objective was to assess this increase by examining changes in histology-specific incidence, treatment, and survival.
  • METHODS: Patients with small bowel malignancies were identified from the National Cancer Data Base (NCDB, 1985-2005) and the Surveillance Epidemiology and End Results (SEER, 1973-2004) database.
  • Treatment and survival trends over time were examined using the National Cancer Data Base.
  • Regression models were developed to assess survival over time.
  • RESULTS: Sixty-seven thousand eight hundred forty-three patients were identified with small bowel malignancies: 37.4% carcinoid, 36.9% adenocarcinomas, 8.4% stromal tumors, and 17.3% lymphomas.
  • Adjuvant chemotherapy utilization for adenocarcinoma increased from 8.1% in 1985 to 23.8% in 2005 (P < 0.0001).
  • Treatment over time was generally unchanged for lymphoma and stromal tumors.
  • Five-year survival after resection remained unchanged over time for all histologic subtypes even after adjusting for changes in patient demographics, tumor characteristics, and treatment approaches.
  • CONCLUSIONS: The overall incidence of small intestine malignancies has increased considerably, primarily because of carcinoid tumors which are now the most common small bowel cancer.
  • With current treatments, survival has remained relatively unchanged over the last 20 years.
  • Novel therapeutic options need to be investigated.
  • [MeSH-major] Intestinal Neoplasms. Intestine, Small
  • [MeSH-minor] Aged. Female. Humans. Incidence. Male. Middle Aged. Survival Rate. Time Factors. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106677.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Higashi D, Ishibashi Y, Tamura T, Nii K, Egawa Y, Koga M, Tomiyasu T, Harimura T, Tanaka R, Futatsuki R, Noda S, Futami K, Maekawa T, Takaki Y, Hirai F, Matsui T: Clinical features of and chemotherapy for cancer of the small intestine. Anticancer Res; 2010 Aug;30(8):3193-7
Genetic Alliance. consumer health - Small intestine cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of and chemotherapy for cancer of the small intestine.
  • BACKGROUND: Cancer of the small intestine is a rare disease, and its clinical features have not been clearly elucidated.
  • Techniques such as double balloon endoscopy and capsule endoscopy allow the preoperative diagnosis of cancer of the small intestine, but this cancer is often detected at an advanced state and in many cases postoperative chemotherapy is required.
  • This study evaluated the pre- and postoperative clinical course of cancer of the small intestine and the effectiveness of chemotherapy.
  • PATIENTS AND METHODS: Patients who underwent surgery for cancer of the small intestine in this Department from July 1985 to December 2008 were included in this study.
  • Duodenal cancer has vastly different origins, methods of diagnosis, and surgical procedures, so this form of cancer was excluded.
  • There were 8 cases of jejunal or ileal cancer treated during the study period.
  • The pre- and postoperative course of these cases was reviewed, as well as the effectiveness of chemotherapy in cases of recurrence.
  • Six patients underwent a partial resection of the small intestine, and a right hemicolectomy, and a bypass were performed in one case each.
  • The tumor type according to Borrmann's classification indicated that 5 tumors were type 2, 2 were type 3, and 1 was type 5; the mean tumor size was 6.3±5.3 (2.5-18.0) cm.
  • Six patients underwent postoperative chemotherapy.
  • One patient underwent adjuvant chemotherapy of, and 5 patients with recurring or advanced cancer underwent therapeutic chemotherapy of.
  • The course of chemotherapy for the 5 patients with recurrent or advanced cancer resulted in 4 patients with progressive disease (PD) and 1 with stable disease (SD).
  • CONCLUSION: The basic treatment for cancer of the small intestine is surgical resection.
  • Palliative surgery and chemotherapy are considered in cases where resection is not possible or the cancer recurs.
  • Nevertheless, there is no established regimen for such chemotherapy.
  • Cancer of the small intestine is currently being treated with chemotherapy based on the treatment strategies for colon cancer, but there are few reports of its success.
  • Chemotherapy was unsuccessful in treating any of the patients with recurring or advanced cancer reviewed in this report.
  • The diagnosis must therefore be improved and postoperative chemotherapy will be needed to treat cancer of the small intestine given its increasing incidence, and therefore physicians are working as quickly as possible to establish an optimal treatment regimen.
  • [MeSH-major] Intestinal Neoplasms / drug therapy. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871040.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Ogata Y, Yamaguchi K, Sasatomi T, Uchida S, Akagi Y, Shirouzu K: [Treatment and outcome in small bowel cancer]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1454-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and outcome in small bowel cancer].
  • In adenocarcinoma of the small intestine, delays in diagnosis are frequent, and the majority of patients present with advanced- stage disease and either lymph node involvement or distant metastatic disease.
  • Surgical resection is a mainstay in treatment of this disease, but the role of adjuvant therapy is unclear.
  • Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma.
  • Further clinical studies on this rare type of tumor are needed.
  • The 72nd Japanese Society for Cancer of the Colon and Rectum have conducted a retrospective review of Japanese patients with adenocarcinoma of the jejunum or ileum.
  • The data indicated that although not statistically significant, there was a trend in median overall survival favoring the chemotherapy for advanced jejunal or ileal adenocarcinoma (17 months vs. 8 months, p=0.114).
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy. Intestine, Small
  • [MeSH-minor] Combined Modality Therapy. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716869.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


11. Chua TC, Koh JL, Yan TD, Liauw W, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol; 2009 Aug 1;100(2):139-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma.
  • BACKGROUND: Small bowel adenocarcinoma is a rare malignancy that presents both a diagnostic and therapeutic challenge.
  • We review our experience with small bowel peritoneal carcinomatosis following treatment with cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC).
  • METHODS: From a prospective database of CRS and PIC, seven patients were identified to have undergone treatment for small bowel peritoneal carcinomatosis with CRS and hyperthermic intraperitoneal chemotherapy (Mitomycin C) and early postoperative intraperitoneal chemotherapy (5FU).
  • Tumor histology of poorly differentiated adenocarcinoma with signet ring, lymphovascular invasion and perineural invasion appeared to be associated with a poor outcome.
  • CONCLUSION: Cytoreductive surgery and perioperative intraperitoneal chemotherapy is a treatment option for small bowel cancer peritoneal carcinomatosis with encouraging survival results.
  • [MeSH-major] Adenocarcinoma / therapy. Hyperthermia, Induced. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / therapy. Prospective Studies

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544356.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Toyokawa A, Nakajima T, Inui K, Yamashita H, Gon H, Kanemitsu K, Tanaka K, Tsukamoto T, Hamabe Y, Ishida T: [A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1167-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].
  • A 50-year-old man undergoing operations for sigmoid colon cancer, small intestine invasion, and liver metastasis was given adjuvant chemotherapy postoperatively.
  • During the course, lung, brain and bone metastasis were found, FOLFIRI therapy was started.
  • Fifth FOLFIRI therapy was performed, but on the night of the next day, he was transported on an emergency basis to our hospital because of a coma.
  • Laboratory examination revealed hyperammonemia, so aminoleban was started for its treatment.
  • Hyperammonemia should be taken into account as a differential diagnosis in the disturbance of consciousness in chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy. Hyperammonemia / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Consciousness Disorders / chemically induced. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged

  • Genetic Alliance. consumer health - Hyperammonemia.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620810.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


13. Lee T, Noda E, Maeda K, Inoue T, Nagahara H, Amano R, Kubo N, Tanaka H, Muguruma K, Takashima T, Yamada N, Yashiro M, Onoda N, Sawada T, Nakata B, Ohira M, Ishikawa T, Hirakawa K: [Two cases of the primary small intestine cancer successfully treated with S-1 and UFT/LV therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2789-91
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of the primary small intestine cancer successfully treated with S-1 and UFT/LV therapy].
  • The primary small intestinal cancer is rare in gastrointestinal cancer, and there are much advanced/recurrent cases.
  • However, there were a few case reports about chemotherapy for advanced or recurrent small intestinal cancer, and a treatment resume was inconsistent.
  • We reported that S-1 and UFT/LV therapy was effective with the two cases as an oral chemotherapy for the primary small intestinal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Jejunal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Drug Combinations. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Oxonic Acid / administration & dosage. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Small intestine cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224714.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; Q573I9DVLP / Leucovorin; 1-UFT protocol
  •  go-up   go-down


14. Kobayashi K, Yano S, Kato K, Tatsukawa T, Ikeda T, Tokushima T: [Case with double primary cancers occurring synchronously in both the lung and jejunum diagnosed according to TTF-1 expression]. Nihon Kokyuki Gakkai Zasshi; 2005 Feb;43(2):84-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case with double primary cancers occurring synchronously in both the lung and jejunum diagnosed according to TTF-1 expression].
  • He received chemotherapy and radiotherapy.
  • The lymph node was near by the Treitz' ligament, and a tumor measuring 30 mm was observed in the jejunum.
  • The differential diagnosis between small intestine metastasis and primary small intestine cancer was difficult.
  • As adenocarcinoma of the jejunum was negative for TTF-1 in immunohistochemical staining and adenocarcinoma of the lung was positive, we diagnosed this patient as having primary jejunal cancer.
  • We report this rare case of double cancer involving the lung and jejunum.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Intestine, Small. Jejunal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Nuclear Proteins / analysis. Transcription Factors / analysis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770938.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


15. Takahashi K, Funayama Y, Tokumura H, Tanda S, Maekawa H, Chiba T, Toshima T, Fukuyama S, Musha H, Matsumura N, Sasaki H, Yasumoto A: [A case of multiple metachronous metastases of colon cancer to the small intestine preoperatively diagnosed by double balloon enteroscopy and radically resected]. Nihon Shokakibyo Gakkai Zasshi; 2010 Feb;107(2):233-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multiple metachronous metastases of colon cancer to the small intestine preoperatively diagnosed by double balloon enteroscopy and radically resected].
  • The patient was a 75-year-old woman who had undergone resection of a transverse colon cancer two years before.
  • She had anemia and intestinal obstruction, and a diagnosis of multiple metastases to the small intestine was made by double balloon enteroscopy.
  • Adjuvant FOLFOX chemotherapy was given, achieving a 26-month disease-free survival.
  • The double balloon enteroscopy was useful in the definitive diagnosis of this case, and aggressive resection with adjuvant chemotherapy contributed to the good outcome.
  • [MeSH-major] Colonic Neoplasms / pathology. Endoscopy, Gastrointestinal / methods. Ileal Neoplasms / secondary. Jejunal Neoplasms / secondary

  • Genetic Alliance. consumer health - Small intestine cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134126.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 26
  •  go-up   go-down


16. Yonemura Y, Tsukiyama G, Miyata R, Sako S, Endou Y, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M, Hagiwara A, Li Y: Indication of peritonectomy for peritoneal dissemination. Gan To Kagaku Ryoho; 2010 Nov;37(12):2306-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 521 patients with peritoneal carcinomatosis (PC) were treated by peritonectomy and perioperative chemotherapy.
  • Each of the 95, 58, 316, 31, 10 and 11 patients were from gastric, colorectal, appendiceal, ovarian, small bowel cancer and mesothelioma, respectively.
  • Peritonectomy was performed with a radical resection of the primary tumor and all gross PC with involved organs, peritoneum, or tissue that was deemed technically feasible and safe for the patient.
  • The survival of gastric cancer patients with a PCI score ≤ 6 was significantly better than those with a PCI score ≥ 7.
  • In appendiceal neoplasm, patients with PCI score less than 28 showed significantly better survival than those with PCI score greater than 29.
  • The survival of colorectal cancer patients with a PCI score ≥ 11 was significantly poorer than those with a PCI score ≤ 10.
  • Among the various prognostic factors in appendiceal neoplasm and gastric cancer patients, CC-0 complete cytoreduction was the most important independent prognostic factor.
  • Peritonectomy is done to remove macroscopic disease and perioperative intraperitoneal chemotherapy to eradicate microscopic residual disease aiming to remove disease completely with a single procedure.
  • Peritonectomy combined with perioperative chemotherapy may achieve long-term survival in a selected group of patients with PC.
  • [MeSH-major] Carcinoma / surgery. Peritoneal Neoplasms / surgery. Peritoneum / surgery
  • [MeSH-minor] Aged. Appendiceal Neoplasms / drug therapy. Appendiceal Neoplasms / surgery. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / surgery. Male. Mesothelioma / drug therapy. Mesothelioma / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Postoperative Complications. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224556.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Naeim A, Dy SM, Lorenz KA, Sanati H, Walling A, Asch SM: Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol; 2008 Aug 10;26(23):3903-10
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based recommendations for cancer nausea and vomiting.
  • The experience of patients living with cancer and being treated with chemotherapy often includes the symptoms of nausea and vomiting.
  • To provide a framework for high-quality management of these symptoms, we developed a set of key targeted evidence-based standards through an iterative process of targeted systematic review, development, and refinement of topic areas and standards and consensus ratings by a multidisciplinary expert panel as part of the RAND Cancer Quality-Assessing Symptoms Side Effects and Indicators of Supportive Treatment Project.
  • For nausea and vomiting, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic chemotherapy, and follow-up after treatment for nausea and vomiting symptoms.
  • In addition, patients with cancer and small bowel obstruction were examined as a special subset of patients who present with nausea and vomiting.
  • The standards presented here for preventing and managing nausea and vomiting in cancer care should be incorporated into care pathways and should become the expectation rather than the exception.
  • [MeSH-major] Antiemetics / therapeutic use. Antineoplastic Agents / adverse effects. Dexamethasone / therapeutic use. Intestinal Obstruction / complications. Morpholines / therapeutic use. Nausea. Neoplasms / drug therapy. Quality Assurance, Health Care. Serotonin 5-HT3 Receptor Antagonists. Vomiting


18. Qureshi I, Awad ZT: Predictors of failure of the laparoscopic approach for the management of small bowel obstruction. Am Surg; 2010 Sep;76(9):947-50
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of failure of the laparoscopic approach for the management of small bowel obstruction.
  • Small bowel obstruction (SBO) is a common cause of hospital admission.
  • Twenty-three consecutive patients underwent diagnostic laparoscopy with curative intent for treatment of SBO by a single surgeon over a 3-year period.
  • The causes of obstruction included adhesive band in 16 patients; and small bowel lymphoma, metastatic esophageal cancer, small bowel gangrene, Meckel diverticulum, gallstones ileus, and incarcerated incisional hernia in two.
  • Using the Fisher two-sided test, no significant predictor for conversion was identified using gender, American Society of Anesthesiologists class, previous bowel obstruction, history of adhesiolysis, abdominal distention, pelvic surgeries, chemotherapy, radiation, malignancy, chronic obstructive pulmonary disease, asthma, coronary artery disease, hypertension, or hypercholesterolenemia.
  • The Wilcoxon two-sided test did not show significance for age, weight, number of previous abdominal surgeries, or small bowel diameter.
  • [MeSH-major] Intestinal Obstruction / surgery. Laparoscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Female. Humans. Laparotomy. Length of Stay. Male. Middle Aged. Retrospective Studies. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836340.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Guckenberger M, Flentje M: Late small bowel toxicity after adjuvant treatment for rectal cancer. Int J Colorectal Dis; 2006 Apr;21(3):209-20
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late small bowel toxicity after adjuvant treatment for rectal cancer.
  • BACKGROUND: For locally advanced rectal cancer surgery as sole treatment results in poor local control and survival.
  • After adjuvant radiotherapy for locally advanced rectal cancer, small bowel toxicity has been the most frequent and serious side effect.
  • The gain in survival and local control was accompanied by severe late chronic toxicity reducing the benefit of adjuvant treatment.
  • REVIEW: Clinical factors, pathology and treatment of late small bowel toxicity after adjuvant radiotherapy for locally advanced rectal cancer will be discussed.
  • This review will focus on different surgical and radiotherapeutic means reducing the risk of late small bowel damage.
  • [MeSH-major] Chemotherapy, Adjuvant / adverse effects. Intestinal Diseases / chemically induced. Intestine, Small / drug effects. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Diarrhea / chemically induced. Hemorrhage / chemically induced. Humans. Intestinal Obstruction / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Oct;10(10):1885-90 [6386762.001]
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Oncology (Williston Park). 1988 Aug;2(8):21-5, 28-9 [3275055.001]
  • [Cites] World J Surg. 1986 Apr;10(2):171-88 [3518250.001]
  • [Cites] Am J Clin Oncol. 1982 Apr;5(2):189-94 [7091042.001]
  • [Cites] Am Surg. 1992 Feb;58(2):132-5 [1550305.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1130-5 [9278661.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Oct;9(10):1445-50 [6415005.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Feb 1;28(3):597-603 [8113102.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Eur J Surg Oncol. 1992 Oct;18(5):487-93 [1426301.001]
  • [Cites] Surg Gynecol Obstet. 1984 Aug;159(2):162-3 [6463828.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):51-7 [9747819.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):455-9 [11567821.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):49-55 [2191763.001]
  • [Cites] Surg Gynecol Obstet. 1985 Apr;160(4):365-6 [3983803.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1213-36 [7713784.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Sep;12(9):1565-73 [3759581.001]
  • [Cites] Surg Gynecol Obstet. 1983 Sep;157(3):269-71 [6612575.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):99-109 [7642437.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Mar;5(3):373-82 [110745.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):581-4 [1623474.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1995;7(3):188-92 [7547523.001]
  • [Cites] J Pathol. 2003 Jul;200(4):500-3 [12845617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):1039-48 [8751414.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):995-8 [10705022.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jan;10(1):55-62 [6698825.001]
  • [Cites] Am Surg. 1994 Jul;60(7):473-82; discussion 482-3 [8010560.001]
  • [Cites] Acta Oncol. 2001;40(8):958-67 [11845961.001]
  • [Cites] Cancer. 1991 Dec 15;68(12):2545-9 [1657360.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):319-24 [9788410.001]
  • [Cites] Cancer. 1977 Mar;39(3):1243-6 [912657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):817-25 [10098437.001]
  • [Cites] Br J Surg. 1973 Oct;60(10 ):814-8 [4748388.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Aug;15(5):233-6 [12924451.001]
  • [Cites] Strahlenther Onkol. 2000 Mar;176(3):105-11 [10742830.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]
  • [Cites] Am J Gastroenterol. 1990 Feb;85(2):121-8 [2301333.001]
  • [Cites] Surg Gynecol Obstet. 1981 Dec;153(6):896-900 [7302817.001]
  • [Cites] Oncology (Williston Park). 1998 Jan;12(1):51-4; discussion 54, 60, 62, passim [9474587.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):885-93 [8478241.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1409-16 [7751886.001]
  • [Cites] Am Surg. 1994 Apr;60(4):282-6 [8129251.001]
  • [Cites] Surgery. 1986 Feb;99(2):133-9 [3484844.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1271-80 [11728687.001]
  • [Cites] Acta Oncol. 1999;38(1):23-32 [10090685.001]
  • [Cites] FASEB J. 2004 May;18(7):816-27 [15117886.001]
  • [Cites] Dis Colon Rectum. 1993 Jun;36(6):564-72 [8500374.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):67-76 [9300741.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Gastroenterology. 1977 Nov;73(5):1093-7 [908489.001]
  • [Cites] J Am Coll Surg. 1999 Dec;189(6):611-24 [10589598.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] J Chir (Paris). 1981 Apr;118(4):221-9 [7228928.001]
  • [Cites] Dis Colon Rectum. 1984 Feb;27(2):89-92 [6697836.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1977 Nov-Dec;2(11-12):1069-74 [599058.001]
  • [Cites] Radiother Oncol. 2003 Jun;67(3):345-9 [12865185.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):469-76 [2394624.001]
  • [Cites] Obstet Gynecol. 1977 Mar;49(3):333-8 [840462.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):968-76 [8780533.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] Dis Colon Rectum. 2001 Dec;44(12):1772-7 [11742161.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1193-8 [10613312.001]
  • [Cites] Radiology. 1974 Sep;112(3):699-703 [4843305.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):896-902 [11550163.001]
  • [Cites] Dis Colon Rectum. 1988 Jan;31(1):17-21 [2835216.001]
  • [Cites] Radiat Res. 2004 Mar;161(3):299-311 [14982484.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):835-40 [10386640.001]
  • [Cites] N Engl J Med. 1985 Jun 6;312(23 ):1465-72 [2859523.001]
  • [Cites] Arch Surg. 2000 Oct;135(10):1212-7 [11030884.001]
  • [Cites] Strahlenther Onkol. 2000 Apr;176(4):161-7 [10812388.001]
  • [Cites] Am J Clin Oncol. 1988 Feb;11(1):25-33 [2829614.001]
  • [Cites] Am J Obstet Gynecol. 1977 Aug 1;128(7):767-71 [879244.001]
  • [Cites] Radiother Oncol. 1994 Aug;32(2):116-23 [7972904.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1336-41 [9369109.001]
  • [Cites] Radiology. 1979 Aug;132(2):479-82 [461811.001]
  • [Cites] Am J Surg. 2001 Sep;182(3):237-42 [11587684.001]
  • [Cites] Strahlenther Onkol. 1995 Aug;171(8):437-43 [7652666.001]
  • (PMID = 16052309.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 89
  •  go-up   go-down


20. Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH: Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemother Pharmacol; 2005 Mar;55(3):263-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumours were predominantly colorectal (30) together with 10 other gastrointestinal, 2 breast, 2 small cell lung and 1 ovarian.
  • All but three patients had received prior chemotherapy.
  • There were two documented partial responses, one in a patient with cancer of the small intestine and the other in a patient with colon cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Administration Schedule. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / adverse effects. Female. Gastrointestinal Tract / drug effects. Humans. Male. Maximum Tolerated Dose. Middle Aged. Topoisomerase I Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592838.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


21. Beyrouti ML, Abid M, Beyrouti R, Ben Amar M, Gargouri F, Frikha F, Affes N, Boujelbene S, Ghorbel A: [Sarcomas of the small intestine]. Presse Med; 2005 Mar 12;34(5):385-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcomas of the small intestine].
  • Sarcomas of the small intestine are rare, clearly differentiated, malignant, mesenchymatous tumours that can be of smooth muscle, Schwann cell or fibroblastic origin.
  • From a clinical point of view, the pain and abdominal mass are the 2 types of symptoms that frequently reveal the disease.
  • In rare cases, sarcomas of the small intestine are manifested by an acute complication.
  • No imaging method can clearly confirm the diagnosis.
  • Before immunohistochemistry, differential diagnosis was made on undifferentiated mesenchymatous "stromal" tumours, which are also rare.
  • Exeresis must be complete and without perforation of the tumour because of the risk of locoregional relapse.
  • The benefits provided by chemotherapy and radiotherapy are limited because of the low mitotic activity of the tumour cells and its weak vascularisation.
  • Long-term survival is limited by poor prognosis criteria: high grade malignancy, size greater than 5 cm, tumour extension, perforation of the tumour, quality of surgical resection and histological type.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859576.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 46
  •  go-up   go-down


22. Hong SH, Koh YH, Rho SY, Byun JH, Oh ST, Im KW, Kim EK, Chang SK: Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol; 2009 Jan;39(1):54-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome.
  • BACKGROUND: Malignant small intestine tumor accounts for 0.1-0.3% of all malignancies.
  • METHODS: We conducted retrospective analysis for the patients with the small intestine adenocarcinoma to explore the clinical characteristics and prognosis.
  • All patients with adenocarcinoma of small intestine diagnosed between March 1997 and March 2007 in the Catholic Medical Center in Korea were identified through the cancer registry.
  • The medical records were reviewed for patient characteristics, treatment and outcome data.
  • Twenty-six patients (49.0%) underwent curative resection and 13 patients receiving adjuvant chemotherapy.
  • Fifteen patients received palliative chemotherapy.
  • Median survival of patients received palliative chemotherapy was 8.0 months (95% CI: 3.5-12.4).
  • CONCLUSIONS: The prognosis of primary adenocarcinoma of small intestine was poor, especially in cases where curative resection could not to be performed.
  • Further study on the methods for early detection and effective systemic chemotherapy should be investigated.
  • [MeSH-major] Adenocarcinoma / pathology. Intestinal Neoplasms / pathology. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Korea. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997182.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


23. Syrigos KN, Vile RG, Peters AM, Harrington KJ: Biodistribution and pharmacokinetics of 111In-dTPA-labelled pegylated liposomes after intraperitoneal injection. Acta Oncol; 2003;42(2):147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes (IDLPL) and unencapsulated 111In-DTPA administered by the intraperitoneal (i.p.) and i.v. routes in non-tumour-bearing mice were compared.
  • A variety of tissues were dissected from 5 min to 192 h to determine the biodistribution and pharmacokinetics.
  • Injection of IDLPL via the i.p. route caused a 74-fold increase in the area under the concentration (AUC) versus time curve in the peritoneum compared to unencapsulated 111In-DTPA.
  • Similarly, the AUC for all the intra-abdominal tissues was increased significantly (20-427-fold).
  • small intestine (1.5-fold).
  • These data support the development of i.p. liposomal chemotherapy for the treatment of intraperitoneal malignant disease.
  • [MeSH-minor] Adrenal Glands / metabolism. Animals. Area Under Curve. Chemistry, Pharmaceutical. Colon / metabolism. Drug Carriers. Drug Delivery Systems. Female. Gallbladder / metabolism. Injections, Intraperitoneal. Injections, Intravenous. Intestine, Small / metabolism. Liposomes. Mice. Ovary / metabolism. Pancreas / metabolism. Peritoneum / metabolism. Specific Pathogen-Free Organisms. Stomach / metabolism. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12801133.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Indium Radioisotopes; 0 / Liposomes; 7A314HQM0I / Pentetic Acid
  •  go-up   go-down


24. Brueck M, Barton M, Rauber K, Zikova A, Kramer W: [Ileus of the small intestine in intestinal marginal-zone B-cell lymphoma of mucoid-associated lymphoid tissue (MALT)]. Dtsch Med Wochenschr; 2001 Dec 7;126(49):1391-5
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileus of the small intestine in intestinal marginal-zone B-cell lymphoma of mucoid-associated lymphoid tissue (MALT)].
  • [Transliterated title] Dünndarmileus bei intestinalem Marginalzonen-B-Zell-Lymphom des MALT.
  • INVESTIGATIONS: Physical examination revealed signs of an acute abdomen with high-pitched bowel sounds and diffuse abdominal guarding.
  • The X-ray showed ileus of the small intestine which required emergency laparotomy.
  • An obstructing conglomerate tumour was present in the area of the ileum, ca.
  • It was removed by partial resection of the small intestine.
  • DIAGNOSIS: Ileus of the small intestine with a low-malignant marginal zone B-cell (non-Hodgkin) lymphoma of MALT type (mucoid-associated lymphoid tissue).
  • TREATMENT AND COURSE: Postoperative staging indicated no further manifestation of the lymphoma.
  • As no radical operation in resecting the tumour had been performed, combined radio- and chemotherapy was undertaken.
  • CONCLUSION: Marginal B-cell lymphomas of the small intestine are only rarely seen in central Europe.
  • Despite its usually slow growth this non-Hodgkin lymphoma of low malignancy can produce an acute mechanical ileus without prodromal symptoms.
  • A multimodal therapeutic approach is often employed, but there are no established treatment strategies.
  • [MeSH-major] Ileal Diseases / etiology. Intestinal Neoplasms / diagnosis. Intestinal Obstruction / etiology. Lymphoma, B-Cell, Marginal Zone / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11740631.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Xavier SG, Fagundes EM, Hassan R, Bacchi C, Conchon M, Tabak DG, Spector N, Zalcberg IR: Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature. Leuk Res; 2003 Nov;27(11):1063-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature.
  • The possibility of an association between the development of granulocytic sarcoma of the small intestine (GSSI) and the M4Eo subtype of AML was suggested in nine previous case reports.
  • Here we report an aleukaemic case of GSSI with inv(16) and its molecular equivalent, the CBFbeta/MYH11 fusion gene, detected by reverse transcriptase-polymerase chain reaction (RT-PCR), that after treatment with conventional AML chemotherapy followed by autologous bone marrow transplantation, achieved complete haematological and molecular remission on bone marrow examination.
  • After chemotherapy, a thickened ileum wall positive for CBFbeta/MYH11 on tumour mass samples was still observed on computed tomography (CT) studies, raising the question of residual GS representing a reservoir of malignant cells.
  • This case demonstrates the critical need of multidisciplinary diagnosis and follow-up of this entity combining immunopathologic, cytogenetic and molecular studies, reinforcing the potentiality of risk-adapted therapy strategies, as it is increasingly claimed for patients with overt AML.
  • [MeSH-major] Intestinal Neoplasms / genetics. Oncogene Proteins, Fusion / genetics. Sarcoma, Myeloid / genetics
  • [MeSH-minor] Adult. Humans. Ileum / radiography. Leukemia / complications. Male. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12859999.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CBFbeta-MYH11 fusion protein; 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 24
  •  go-up   go-down


26. Brown RS, Yassin J, Colville DH, Harland SJ, Payne HA: First report of an isolated jejunal seminoma: presentation with melaena and iron deficiency anaemia. Clin Oncol (R Coll Radiol); 2001;13(6):455-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case history of a man with isolated seminoma in the jejunum and abnormal testes but no provable malignant testicular disease.
  • Treatment with cisplatin-based chemotherapy led to complete resolution of the jejunal seminoma.
  • The rarity of seminoma involving the small bowel is highlighted.
  • The possible origins of this tumour are discussed.
  • [MeSH-major] Anemia, Iron-Deficiency / diagnosis. Jejunal Neoplasms / diagnosis. Melena / diagnosis. Seminoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Cryptorchidism / pathology. Etoposide / administration & dosage. Humans. Intestine, Small / pathology. Male. Middle Aged. Testicular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11824886.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Alzubi A, Zöllei I, Krenács L, Intzédy K, Hudák J: [Primary T-cell lymphoma of the small bowel]. Magy Seb; 2008 Apr;61(2):79-83
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary T-cell lymphoma of the small bowel].
  • Primary malignancies in the small intestine are relatively rare.
  • The authors report a case of a primary T-cell lymphoma in the small bowel that caused diagnostic challenges.
  • Blood tests, endoscopic examinations, ultrasonography and CT scan could not reveal a definitive diagnosis.
  • While a small bowel follow through examination demonstrated an entero-enteral fistula, its exact position could not have been determined.
  • Consequently, an exploratory laparotomy was carried out, and a tumour was found involving the small bowel loops.
  • The involved portion of the small intestine (with the fistula) was resected, and a side-to-side small bowel anastomosis was performed.
  • Histological and immunohistochemical analyses revealed a primary T-cell lymphoma of the small bowel.
  • There was no evidence of metastatic disease at the time of surgery.
  • The patient received adjuvant chemotherapy, but three months later multiple lung metastases were detected.
  • Small bowel malignant tumours cause significant diagnostic difficulties.
  • Therefore, diagnosis and adequate treatment are usually delayed for some weeks.
  • Nevertheless, surgical exploration and resection of the tumour will be necessary for the correct diagnosis and treatment.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / surgery. Intestine, Small / pathology. Lung Neoplasms / secondary. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Intestinal Fistula / diagnosis. Intestinal Fistula / surgery. Laparotomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426712.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


28. Croom KF, Perry CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs; 2003;63(5):513-22; discussion 523-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
  • The KIT tyrosine kinase is abnormally expressed in gastrointestinal stromal tumour (GIST), a rare neoplasm for which there has been no effective systemic therapy.
  • Similar response rates were reported in a smaller, dose-escalation study, in which objective tumour response was a secondary endpoint.
  • Severe or serious adverse events occurred in 21% of patients in the larger study, and included gastrointestinal or tumour haemorrhage.
  • A major focus of cancer research in recent years has been to identify oncogenic molecules and the signal transduction pathways in which they are involved, in order to develop specifically targeted drugs.
  • One such drug is imatinib mesylate (imatinib, Glivic/Gleevec), an orally administered 2-phenylaminopyrimidine derivative that is a competitive inhibitor of the tyrosine kinases associated with platelet-derived growth factor (PDGF) receptors, the Abelson (ABL) protein and the KIT protein (also known as stem cell factor [SCF] receptor).
  • Imatinib was initially evaluated for the treatment of chronic myeloid leukaemia (CML) [reviewed previously in Drugs].
  • More recently, imatinib has been approved for the treatment of patients with advanced gastrointestinal stromal tumour (GIST), in which KIT, a tyrosine kinase receptor, is abnormally expressed.
  • GISTs are soft tissue gastrointestinal sarcomas probably arising from mesenchymal cells.
  • They are rare neoplasms, with between 5000 and 10 000 new cases being diagnosed each year in the US.
  • GISTs occur throughout the gastrointestinal tract but the stomach and small intestine are the most common sites.
  • Symptoms depend on the site and size of the tumour, and may include abdominal pain, gastrointestinal bleeding or signs of obstruction; small tumours may be asymptomatic.
  • The diagnosis of GIST is made by immunohistochemical staining for CD117, a cell surface antigen on the extracellular domain of KIT, in conjunction with pathological examination of tissue with light microscopy.
  • All GISTs may have some degree of malignant potential.
  • They are unresponsive to standard chemotherapy and to radiotherapy, and the mainstay of treatment in the past has been surgery.
  • However, recurrence rates are high, and there has been no effective systemic treatment for unresectable GIST or metastatic disease.
  • Gain-of-function mutations of the KIT proto-oncogene occur in up to 90% of GISTs, allowing constitutive activation of tyrosine kinase (i.e. auto-phosphorylation of tyrosine residues independent of ligand-receptor binding), leading to aberrant cell division and tumour growth.
  • This article summarises the pharmacology, efficacy and tolerability profile of imatinib in the treatment of patients with advanced GIST.
  • [MeSH-major] Antineoplastic Agents. Gastrointestinal Neoplasms / drug therapy. Piperazines. Pyrimidines. Stromal Cells / pathology
  • [MeSH-minor] Benzamides. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacokinetics. Enzyme Inhibitors / pharmacology. Enzyme Inhibitors / therapeutic use. Humans. Imatinib Mesylate. Multicenter Studies as Topic. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2001 Jun;32(6):578-82 [11431711.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):5054-8 [11526490.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):485-91 [12057094.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Anticancer Drugs. 2002 Sep;13(8):847-9 [12394270.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 20;91(2):163-8 [9923858.001]
  • [Cites] Blood. 2000 Aug 1;96(3):925-32 [10910906.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Science. 2000 Sep 15;289(5486):1938-42 [10988075.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3898-905 [12228211.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5143-50 [11016641.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3319-26 [10955819.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 17):3-8 [11740801.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):683-93 [11870247.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Clin Invest. 2000 Jan;105(1):3-7 [10619854.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3719-23 [10446987.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4947-52 [9389713.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5778-83 [11479215.001]
  • [Cites] Biochim Biophys Acta. 1997 Dec 9;1333(3):F217-48 [9426205.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4879-83 [12208734.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Drugs. 2001;61(12):1765-74; discussion 1775-6 [11693465.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7 [12528778.001]
  • (PMID = 12600228.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 45
  •  go-up   go-down


29. Kelleher FC, McDermott R: The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer; 2010 Sep;46(13):2357-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
  • The anaplastic lymphoma kinase gene (ALK) is a gene on chromosome 2p23 that has expression restricted to the brain, testis and small intestine but is not expressed in normal lymphoid tissue.
  • It has similarity to the insulin receptor subfamily of kinases and is emerging as having increased pathologic and potential therapeutic importance in malignant disease.
  • This gene was originally established as being implicated in the pathogenesis of rare diseases including inflammatory myofibroblastic tumour (IMT) and ALK-positive anaplastic large cell lymphoma, which is a subtype of non-Hodgkin's lymphoma.
  • In 2007, an inversion of chromosome 2 involving ALK and a fusion partner gene in a subset of non-small cell lung cancer was discovered.
  • In 2008, publications emerged implicating ALK in familial and sporadic cases of neuroblastoma, a childhood cancer of the sympatho-adrenal system.
  • This has been described in ALK-positive anaplastic large cell lymphoma in which ALK is fused to NPM (nucleolar protein gene) and in non-small cell lung cancer where ALK is fused to EML4 (Echinoderm microtubule-associated protein 4).
  • The most frequently described partner genes in inflammatory myofibroblastic tumour are tropomyosin 3/4 (TMP3/4), however in IMTs a diversity of ALK fusion partners have been found, with the ability to homodimerise a common characteristic.
  • Point mutations and amplification of the ALK gene occur in the childhood cancer neuroblastoma.
  • Therapeutic targeting of ALK fusion genes using tyrosine kinase inhibition, vaccination using an ALK specific antigen and treatment using viral vectors for RNAi are emerging potential therapeutic possibilities.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 2 / genetics. Neoplasms / genetics. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / therapy. Drug Synergism. Gene Amplification. Humans. Lung Neoplasms / genetics. Lung Neoplasms / therapy. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / therapy. Mutation / genetics. Neuroblastoma / genetics. Neuroblastoma / therapy. Pyrimidines / therapeutic use. Pyrroles / therapeutic use. Receptor Protein-Tyrosine Kinases. Receptor, IGF Type 1 / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20451371.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GSK 1838705A; 0 / Pyrimidines; 0 / Pyrroles; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down






Advertisement